Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Bolt Biotherapeutics, Inc. (BOLT)
Company Research
Source: GlobeNewswire
BDC-4182 demonstrated compelling anti-tumor activity and an acceptable safety profile in preclinical studies BDC-4182 outperformed cytotoxic claudin 18.2 ADCs in syngeneic model Learnings from BDC-1001 data suggest Boltbody™ ISACs with enhanced immune activation could offer greater efficacy, warranting further testing REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today presented updated preclinical data for BDC-4182, a next-generation Boltbody™ ISAC clinical candidate targeting claudin 18.2, and provided key learnings from its Phase 1 dose-escalation trial of BDC-1001 at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held in Houston, Texas from November 6-10, 2024. “We are encouraged by the preclinical BDC-4182 data presented at SITC. Most notably, our next-generation claudin 18.2 ISAC elicits b
Show less
Read more
Impact Snapshot
Event Time:
BOLT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BOLT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BOLT alerts
High impacting Bolt Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BOLT
News
- Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]Yahoo! Finance
- Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) had its "neutral" rating re-affirmed by analysts at HC Wainwright.MarketBeat
- Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
- Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
BOLT
Earnings
- 11/12/24 - Miss
BOLT
Analyst Actions
- 11/13/24 - HC Wainwright
BOLT
Sec Filings
- 12/23/24 - Form 8-K
- 11/14/24 - Form SC
- 11/12/24 - Form 10-Q
- BOLT's page on the SEC website